The Tough Tech problem we are solving
Manufacturing next-generation cell and gene therapies is one of the most complex and resource-intensive challenges in modern medicine. These therapies hold immense potential to cure previously untreatable diseases, yet their production remains slow, manual, and difficult to scale. Each dose must be customized to an individual patient, requiring precision processes that are highly sensitive to contamination and human error. The lack of scalable, automated systems limits access, increases costs, and delays delivery for patients who need life-saving treatments.
About our solution
Multiply Labs is transforming biomanufacturing through advanced robotics designed to automate and scale the production of precision medicines. Their modular robotic systems integrate seamlessly with leading Good Manufacturing Practice (GMP) instruments, allowing companies to configure and scale their processes efficiently and safely. By enabling high-throughput production through multiple parallel modules, Multiply Labs’ platform reduces variability, boosts efficiency, and accelerates manufacturing timelines. Through this fusion of robotics and bioprocess engineering, Multiply Labs is building the foundation for a future where every patient can access high-quality, personalized cell and gene therapies.